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BACKGROUND
The use of levothyroxine to treat subclinical hypothyroidism is controversial. We 
aimed to determine whether levothyroxine provided clinical benefits in older persons 
with this condition.
METHODS
We conducted a double-blind, randomized, placebo-controlled, parallel-group trial 
involving 737 adults who were at least 65 years of age and who had persisting sub-
clinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine 
level within the reference range). A total of 368 patients were assigned to receive levo-
thyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg 
or the patient had coronary heart disease), with dose adjustment according to the 
thyrotropin level; 369 patients were assigned to receive placebo with mock dose ad-
justment. The two primary outcomes were the change in the Hypothyroid Symptoms 
score and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year 
(range of each scale is 0 to 100, with higher scores indicating more symptoms or 
tiredness, respectively; minimum clinically important difference, 9 points).
RESULTS
The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. 
The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year, 
this level had decreased to 5.48 mIU per liter in the placebo group, as compared with 
3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. 
We found no differences in the mean change at 1 year in the Hypothyroid Symptoms 
score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; be-
tween-group difference, 0.0; 95% confidence interval [CI], −2.0 to 2.1) or the Tired-
ness score (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI, 
−2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome 
measures. There was no significant excess of serious adverse events prespecified as 
being of special interest.
CONCLUSIONS
Levothyroxine provided no apparent benefits in older persons with subclinical hypo-
thyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.gov 
number, NCT01660126.)
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Subclinical hypothyroidism is de-fined as an elevated serum thyrotropin level and a serum free thyroxine level 
within the reference range.1 Between 8% and 
18% of adults 65 years of age or older have these 
biochemical features, and the prevalence is higher 
among women than among men.2
Subclinical hypothyroidism is a possible con-
tributor to many problems in older persons. Thy-
roid hormones have multiple effects, since they 
act as an essential regulatory factor in numerous 
physiological systems, including the vascular 
tree and the heart,3 the brain (including cogni-
tion),4 skeletal muscle, and bone.5 Tiredness is 
the most important symptom of overt hypothy-
roidism,6 but most patients with subclinical hypo-
thyroidism have no symptoms or have nonspecific 
symptoms.7 There is a convincing epidemio-
logic association with subsequent coronary heart 
disease.8
Randomized, controlled trials of levothyroxine 
replacement for the treatment of subclinical hypo-
thyroidism have been small9,10 and have yielded 
only limited evidence regarding the possible ben-
efits and risks of treatment.1 We aimed to deter-
mine whether there are clinical benefits from 
levothyroxine replacement in older persons with 
subclinical hypothyroidism.
Me thods
Trial Overview
The trial protocol, which was published previ-
ously11 and is available with the full text of this 
article at NEJM.org, was approved by the relevant 
ethics committees and regulatory authorities in 
all the countries involved in the trial. Partici-
pants provided written informed consent.
The trial was conducted in accordance with 
the principles of the Declaration of Helsinki12 
and Good Clinical Practice guidelines.13 The 
Robertson Centre for Biostatistics at the Univer-
sity of Glasgow was the trial data and biostatis-
tics center.
The European Union FP7 provided primary 
financial support for the conduct of the trial. 
Supplies of levothyroxine and matching placebo 
were provided free of charge by Merck (Darm-
stadt, Germany). The funder, the trial sponsors 
(NHS Greater Glasgow and Clyde Health Board 
and University of Glasgow, United Kingdom; 
University College Cork, Ireland; Leiden Univer-
sity Medical Center, the Netherlands; and Uni-
versity of Bern and Bern University Hospital, 
Switzerland), and Merck played no role in the 
design, analysis, or reporting of the trial. The 
main sponsor (NHS Greater Glasgow and Clyde 
Health Board) contributed to the writing of the 
protocol. None of the sponsors had any involve-
ment in the analysis or the reporting of the re-
sults. The authors vouch for the accuracy and 
completeness of the data and analyses reported 
and for the fidelity of the trial to the protocol.
Participants
Participants were identified from clinical labora-
tory and general practice databases and records. 
The inclusion criteria were an age of 65 years or 
more and persistent subclinical hypothyroidism, 
defined as an elevated thyrotropin level (4.60 to 
19.99 mIU per liter) that was measured on at least 
two occasions that were 3 months to 3 years 
apart, with the free thyroxine level within the 
reference range. The main exclusion criteria for 
the trial were a current prescription for levothy-
roxine, antithyroid drugs, amiodarone, or lithium; 
thyroid surgery or receipt of radioactive iodine 
within the previous 12 months; dementia; hos-
pitalization for a major illness or an elective 
surgery within the previous 4 weeks; an acute 
coronary syndrome (including myocardial in-
farction or unstable angina) within the previous 
4 weeks; and terminal illness.11
Trial Design and Regimen
We conducted a randomized, double-blind, par-
allel-group trial of levothyroxine versus placebo. 
Patients underwent randomization in a 1:1 ratio, 
with stratification according to country, sex, and 
starting dose, with the use of randomly permuted 
blocks.
The active intervention started with levothy-
roxine at a dose of 50 μg daily (or 25 μg in 
patients with a body weight of <50 kg or with 
known coronary heart disease [previous myocar-
dial infarction or symptoms of angina pectoris]) 
or matching placebo. Dose adjustment in the levo-
thyroxine group was aimed to result in a thyro-
tropin level within the reference range (0.40 to 
4.59 mIU per liter). Details regarding how the 
dose was adjusted and the mock adjustment in 
the placebo group are provided in the Supple-
mentary Appendix, available at NEJM.org. All dose 
adjustments were generated and executed by 
means of computer without the intervention of 
a physician. The participants, investigators, and 
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treating physicians were unaware of the results 
of thyrotropin measurements throughout the 
course of the trial.
Procedures and Outcomes
The two primary outcomes for the trial were the 
change from baseline to 12 months in the Thyroid-
Related Quality-of-Life Patient-Reported Outcome 
measure (ThyPRO) Hypothyroid Symptoms score 
(4 items) and Tiredness score (7 items); each 
scale ranges from 0 to 100, with higher scores 
indicating more symptoms and tiredness, respec-
tively.14 A recent systematic review recommended 
ThyPRO as the preferred measurement tool for 
the assessment of health-related quality of life in 
patients with benign thyroid disease.15 The ThyPRO 
and other instruments were administered in En-
glish, French, German, or Dutch as appropriate. 
We had initially planned for cardiovascular events 
and thyroid-specific quality of life to be the two 
primary outcomes. However, this plan was mod-
ified during the trial to thyroid-specific quality-
of-life scores as the two primary outcomes and 
cardiovascular events as a secondary outcome 
when it became apparent that the trial would be 
underpowered for cardiovascular events owing 
to delays and difficulties in recruitment.11
The secondary outcomes included changes 
from baseline in generic health-related quality of 
life (as assessed by the EuroQoL [EQ] Group 
5-Dimension Self-Report Questionnaire [EQ-5D]; 
scores on the EQ-5D descriptive index range 
from −0.59 to 1.00, and scores on the EQ visual-
analogue scale range from 0 to 100, with higher 
scores indicating better quality of life),16 compre-
hensive thyroid-related quality of life (as assessed 
by the ThyPRO-39 score, a shorter version of the 
ThyPRO measure,17 at final follow-up only), hand-
grip strength (as assessed by means of the Jamar 
isometric dynamometer, with the recorded score 
as the best of three measures in the dominant 
hand),18 executive cognitive function (as assessed 
with the letter–digit coding test, which indicates 
the speed of processing according to the number 
of correct responses in matching nine letters 
with nine digits in 90 seconds; minimum score, 
0, with higher scores indicating better executive 
cognitive function; there is no maximum score),19 
blood pressure (systolic and diastolic), weight, 
body-mass index, waist circumference, activities 
of daily living (as assessed by the Barthel Index 
of functional levels in activities of daily living, 
on a scale ranging from 0 to 20, with higher 
scores indicating better performance),20 the In-
strumental Activities of Daily Living score (on a 
scale from 0 to 14, with higher scores indicating 
better performance in activities of daily living),21 
and fatal and nonfatal cardiovascular events. The 
minimum follow-up was 1 year, and the maxi-
mum follow-up was 3 years.
Safety and Recording of Adverse Events
Adverse events were assessed, managed, recorded, 
reported, and analyzed in accordance with the 
Medicines for Human Use (Clinical Trials) Regu-
lations 2004 (as amended). Adverse events of 
special interest included new atrial fibrillation, 
heart failure, fracture, and new diagnosis of 
osteoporosis. The score on the ThyPRO Hyper-
thyroid Symptoms scale was recorded as a mea-
sure of possible adverse effects (on a scale from 
0 to 100, with higher scores indicating more 
symptoms; minimum clinically important dif-
ference has been estimated as 9 points).14
Statistical Analysis
The Hypothyroid Symptoms and Tiredness scores 
from the ThyPRO14 were the two primary out-
comes, with the required P value for statistical 
significance split equally to each test (0.05/2 = 0.025 
for each test). We assumed standard deviations for 
data at 1 year of 13.3 and 18.3 on the 100-point 
scales, respectively, after adjustment for baseline 
values. These calculations provided the trial with 
80% power to detect a change with levothyroxine 
treatment (vs. placebo) of 3.0 points on the Hypo-
thyroid Symptoms score and 4.1 points on the 
Tiredness score with our revised maximum ex-
pected number of recruited participants of 750, 
and with changes of 3.5 points and 4.9 points, 
respectively, with our minimum expected number 
of 540 participants. Justification for these power 
calculations is provided in the trial protocol.11
The methods of analysis of the continuous 
efficacy outcomes involving measurements at 
baseline and follow-up were analyzed at each 
time point for the comparison of the two trial 
groups, with adjustment for stratification vari-
ables (country, sex, and starting dose of levothy-
roxine) and baseline levels of the same variable 
with the use of multivariate linear regression 
(see the Supplementary Appendix). The efficacy 
and safety analyses were carried out in a modi-
fied intention-to-treat population, which included 
participants with data on the outcome of inter-
est. Patients who discontinued the trial regimen 
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continued to be followed for the modified inten-
tion-to-treat analysis. These analyses were sup-
ported with sensitivity analyses that used mixed-
effects models and multiple imputations for 
missing data. The primary and secondary out-
comes at 12 months were also analyzed in pre-
specified subgroups according to sex and base-
line thyrotropin level.11 Analyses were repeated in 
the per-protocol population, which included par-
ticipants who continued to take the trial regimen 
per the trial protocol.
R esult s
Trial Population
We screened 2647 community-dwelling persons 
who were at least 65 years of age and who were 
identified as having biochemical subclinical hypo-
thyroidism. A total of 737 participants under-
went randomization, 369 of whom were assigned 
to receive placebo and 368 to receive levothyrox-
ine (Fig. 1). The characteristics at baseline were 
similar in the two groups (Table 1, and Table S1 
in the Supplementary Appendix). The mean age 
of the patients was 74.4 years, and 396 patients 
(53.7%) were women. A score of 0 (indicating no 
symptoms) at baseline was observed in 199 of 737 
participants (27.0%) on the Hypothyroid Symp-
toms scale and in 64 (8.7%) on the Tiredness 
scale; 36 participants (4.9%) had a score of 0 in 
both domains.
A total of 337 participants (91.3%) who were 
randomly assigned to the placebo group com-
pleted 12-month follow-up, as did 332 (90.2%) in 
the levothyroxine group. The median follow-up 
for all the participants who underwent random-
ization (including participants who discontinued 
the trial regimen) was 17.3 months (interquartile 
range, 12.0 to 24.4) in the placebo group and 
18.0 months (interquartile range, 11.0 to 25.4) 
in the levothyroxine group. The median dose of 
levothyroxine at 1 year was 50 μg. The numbers 
of patients who were included in the analyses 
are presented in Figure 1.
Thyroid-Function Tests
The mean (±SD) thyrotropin level at baseline was 
6.40±2.01 mIU per liter. The thyrotropin levels 
were reduced from baseline to a greater extent in 
the levothyroxine group than in the placebo 
group at all time points of review, with a mean 
between-group difference of 2.29 mIU per liter 
at 6 to 8 weeks after randomization (P<0.001) 
(Table S2 in the Supplementary Appendix). At 
12 months, the mean thyrotropin level was 
5.48±2.48 mIU per liter in the placebo group, as 
compared with 3.63±2.11 mIU per liter in the 
levothyroxine group, resulting in a between-
group difference of 1.92 mIU per liter (P<0.001) 
(Table 2 and Fig. 2). There was a significant in-
teraction between the trial group and the office 
visit (P = 0.03), with a reduction in the thyrotro-
pin level being the greatest at 6 to 8 weeks.
Figure 1. Randomization, Follow-up, and Dose Levels.
Exclusions for other reasons included use of antithyroid medication (in 17 
persons), recent thyroid surgery (in 1), recent acute coronary syndrome (in 1), 
current participation in another trial (in 1), and adrenal insufficiency (in 1). 
Two patients who were excluded because the thyrotropin level reverted to 
less than 4.60 mIU per liter also had an additional exclusion of galactose 
intolerance. Extended follow-up beyond 12 months was conducted in a 
subgroup of patients, with a median duration of follow-up from baseline  
of 24.2 months (interquartile range, 18.4 to 30.3) in the placebo group and 
24.5 months (interquartile range, 18.4 to 30.5) in the levothyroxine group.
737 Underwent randomization
2647 Adults were screened
for eligibility
1910 Were excluded
1666 Did not meet
inclusion criteria
1645 Had reversion of thyrotro-
pin level to <4.60 mIU/liter
21 Had other reason
244 Did not proceed
to randomization
369 Were assigned to receive
placebo
368 Were assigned to receive
levothyroxine
337 Were included in 12-mo follow-up
30 Received 25 µg
237 Received 50 µg
33 Received 75 µg
8 Received 100 µg
29 Discontinued placebo
320 Had primary-outcome data
332 Were included in 12-mo follow-up
27 Received 25 µg
226 Received 50 µg
26 Received 75 µg
14 Received 100 µg
39 Discontinued levothyroxine
318 Had primary-outcome data
187 Were included in extended follow-up
8 Received 25 µg
111 Received 50 µg
29 Received 75 µg
10 Received 100 µg
1 Received 125 µg
28 Discontinued placebo
194 Were included in extended follow-up
12 Received 25 µg
108 Received 50 µg
32 Received 75 µg
9 Received 100 µg
2 Received 125 µg
31 Discontinued levothyroxine
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Free thyroxine levels were not routinely mea-
sured, although the data were available in a sub-
group of patients. The mean free thyroxine level 
was 2.3 pmol per liter (0.2 ng per deciliter) 
higher in the levothyroxine group than in the 
placebo group both at 6 to 8 weeks and at 12 
months (P<0.001 for both comparisons) (Table S3 
in the Supplementary Appendix).
Thyroid-Specific Quality of Life
The mean Hypothyroid Symptoms score at 12 
months (with adjustment for baseline score) was 
16.7±17.5 in the placebo group and 16.6±16.9 in 
the levothyroxine group (P = 0.99). The mean 
Tiredness score was 28.6±19.5 in the placebo 
group and 28.7±20.2 in the levothyroxine group 
(P = 0.77). We found no differences in the mean 
change at 1 year in the Hypothyroid Symptoms 
score (0.2±15.3 in the placebo group and 0.2±14.4 
in the levothyroxine group) or the Tiredness score 
(3.2±17.7 and 3.8±18.4, respectively) (Table 2). 
There were no significant between-group differ-
ences in either of these measures at 6 to 8 weeks 
(Table S4 in the Supplementary Appendix). There 
was a small-magnitude between-group difference 
in the Tiredness score, with a lower value in the 
levothyroxine group than in the placebo group 
(difference, −3.49; P = 0.05) at the extended fol-
Characteristic
Placebo Group 
(N = 369)
Levothyroxine Group 
(N = 368)
Age — yr
Mean 74.8±6.8 74.0±5.8
Range 65.1–93.4 65.2–93.0
Female sex — no. (%) 198 (53.7) 198 (53.8)
White race — no. (%)† 362 (98.1) 362 (98.4)
Standard housing — no. (%)‡ 356 (96.5) 358 (97.3)
Previous medical conditions and clinical descriptors — no./total no. (%)
Ischemic heart disease§ 50/369 (13.6) 50/368 (13.6)
Atrial fibrillation 44/368 (12.0) 45/364 (12.4)
Hypertension 183/366 (50.0) 192/368 (52.2)
Diabetes mellitus 54/368 (14.7) 63/368 (17.1)
Osteoporosis 47/367 (12.8) 41/364 (11.3)
Current smoking 33/369 (8.9) 29/368 (7.9)
Median no. of concomitant medicines (IQR) 4 (2–6) 4 (2–6)
Median Mini–Mental State Examination score (IQR)¶ 29 (28–30) 29 (27–30)
Weight <50 kg — no. (%) 5 (1.4) 5 (1.4)
Laboratory results
Thyrotropin — mIU/liter 6.38±2.01 6.41±2.01
Median (IQR) 5.76 (5.10–6.94) 5.73 (5.12–6.83)
Range 4.60–17.60 4.60–17.60
Free thyroxine — pmol/liter‖ 13.3±1.9 13.4±2.1
Outcome measures**
Hypothyroid Symptoms score 16.9±17.9 17.5±18.8
Tiredness score 25.5±20.3 25.9±20.6
EQ-5D descriptive index 0.847±0.171 0.846±0.187
EQ visual-analogue scale score 76.5±16.3 78.4±15.3
Hand-grip strength — kg 27.5±11.3 28.0±10.2
Letter–digit coding test score 25.2±8.3 24.9±7.4
Blood pressure — mm Hg
Systolic 140.4±18.9 141.2±18.7
Diastolic 74.8±11.7 74.1±11.6
Body-mass index 27.7±4.6 28.1±5.3
Table 1. Characteristics of the Participants at Baseline.*
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low-up review (Table 2). Prespecified analyses 
according to sex and baseline thyrotropin level 
did not reveal any subgroups of patients who 
benefited from treatment with levothyroxine. 
Per-protocol analyses and sensitivity analyses 
with the use of multiple imputation of missing 
values showed no significant differences be-
tween the levothyroxine group and the placebo 
group (Tables S4 and S5 in the Supplementary 
Appendix).
Other Outcome Measures
The EQ-5D descriptive index showed a small 
deterioration at 12 months (mean difference be-
tween the levothyroxine group and the placebo 
group, −0.025; P = 0.05) but a minor improve-
ment at extended follow-up (mean difference, 
0.040; P = 0.03); there were no significant between-
group differences at 6 to 8 weeks. There were no 
significant between-group differences in the score 
on the EQ visual-analogue scale (Table 2, and 
Table S2 in the Supplementary Appendix).
No significant effects were seen in any of the 
other secondary-outcome measures, either in the 
modified intention-to-treat or per-protocol analy-
ses or in the prespecified subgroups (Table 2, 
and Tables S4, S6, S7, and S8 in the Supplemen-
tary Appendix). Results regarding cardiovascular 
events and total and cardiovascular mortality are 
provided in Table 3 and in Figures S1 and S2 in 
the Supplementary Appendix.
Adverse Effects and Events
We found no significant difference in the Hy-
perthyroid Symptoms score (according to the 
ThyPRO assessment) with levothyroxine, as com-
pared with placebo, at any time point (Table 2, 
and Table S2 in the Supplementary Appendix). 
The incidence of serious adverse events of spe-
cial interest (atrial fibrillation, heart failure, 
fracture, or new diagnosis of osteoporosis) was 
similar in the two groups (Table 3). The number 
of patients with at least one serious adverse 
event was slightly higher in the placebo group 
than in the levothyroxine group (P = 0.049), as 
was the total number of serious adverse events. 
However, we observed no pattern of event type 
that contributed to this difference. The propor-
tions of patients who discontinued the trial 
regimen or who withdrew from follow-up were 
similar in the two groups (Table 3).
Discussion
In this multicenter, double-blind, randomized, 
placebo-controlled, parallel-group trial involving 
Characteristic
Placebo Group 
(N = 369)
Levothyroxine Group 
(N = 368)
Waist circumference — cm 97.5±12.8 98.5±13.6
Median Barthel Index (IQR) 20 (14–20) 20 (13–20)
Median Instrumental Activities of Daily Living score (IQR) 14 (7–14) 14 (7–14)
*  Plus–minus values are means ±SD. There were no significant between-group differences in the baseline characteristics. 
IQR denotes interquartile range.
†  Race was reported by the patient.
‡  Standard housing was defined as nonsheltered community accommodation. By contrast, sheltered housing is purpose-
built grouped housing for older persons, often with an on-site manager or warden.
§  Ischemic heart disease was defined as a history of angina pectoris or previous myocardial infarction.
¶  The Mini–Mental State Examination score is on a scale from 0 to 30, with higher scores indicating better cognitive 
function.
‖  To convert the values for free thyroxine to nanograms per deciliter, divide by 12.87.
**  The Hypothyroid Symptoms score and the Tiredness score from the Thyroid-Related Quality of Life Patient-Reported 
Outcome (ThyPRO) questionnaire are each assessed on a scale from 0 to 100, with higher scores indicating more 
symptoms and tiredness, respectively. The minimum clinically important difference for each score has been estimated 
as 9 points. The EuroQoL [EQ] Group 5-Dimension Self-Report Questionnaire (EQ-5D) scores included both the EQ-
5D descriptive index (on a scale from −0.59 to 1.00) and the score on the EQ visual-analogue scale (on a scale from  
0 to 100); higher scores on each scale indicate better quality of life. The score on the letter–digit coding test (a test  
of executive cognitive function) indicates the speed of processing according to the number of correct responses in 
matching nine letters with nine digits in 90 seconds (minimum score is 0, with higher scores indicating better execu-
tive cognitive function; there is no maximum score). The body-mass index is the weight in kilograms divided by the 
square of the height in meters. The Barthel Index uses a scale from 0 to 20 points, with higher numbers indicating 
better performance on activities of daily living. The Instrumental Activities of Daily Living scale has a maximum score 
of 14 (range, 0 to 14), with higher scores indicating better performance in activities of daily living.
Table 1. (Continued.)
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older participants with subclinical hypothyroid-
ism, treatment with levothyroxine was associated 
with a persistently lower serum thyrotropin level 
than was placebo (between-group difference, ap-
proximately 2 mIU per liter), with the maximum 
effects seen at time of first review (6 to 8 weeks). 
We found that levothyroxine had no consistent 
beneficial effect on thyroid-related symptoms. 
This finding was true in both older men and 
older women and for different thyrotropin levels 
at baseline. Our trial had good statistical power 
to detect a clinically meaningful effect on thy-
roid-related quality of life, with 95% confidence 
intervals that excluded a beneficial effect greater 
than 2.1 points (on a scale from 0 to 100) in 
either of the two primary outcomes. If a symp-
tom benefit was to have occurred, it would have 
been expected to be seen at 12 months.
The subsequent small-magnitude between-
group difference in tiredness with levothyroxine 
versus placebo in the subgroup of patients who 
had extended follow-up is likely to be a chance 
finding. In contrast, an observational study of 
the treatment of autoimmune hypothyroidism in 
middle-age participants (median baseline thyro-
tropin level, 8.1 mIU per liter) showed that the 
Tiredness score improved markedly (reduction of 
12 points at 6 months) and that the Hypothyroid 
Symptoms score also was reduced (by 2 points).22 
A small reduction in tiredness has previously 
been shown in a short-term trial of levothyroxine 
for the treatment of subclinical hypothyroidism 
in 120 middle-age participants.23 There are limit-
ed data from high-quality, randomized, controlled 
trials regarding the effects of levothyroxine re-
placement in older persons with subclinical hy-
pothyroidism.1 Studies have generally been small 
(≤120 participants) and underpowered, often fo-
cusing on younger participants and with a short 
duration of follow-up.9,10
Levothyroxine treatment yielded no significant 
beneficial effects on a range of secondary-out-
come measures. We found a slight deterioration 
(of borderline statistical significance) in the EQ-5D 
descriptive index with levothyroxine versus pla-
cebo at 12 months but an improvement versus 
placebo in the subgroup of patients who com-
pleted extended follow-up (median, 24.5 months). 
The effects we observed were in opposite direc-
tions at these different time points and were of 
very small magnitude (−0.025 at 12 months and 
0.040 at extended follow-up), and therefore these *  A
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are likely to be random chance findings. The 
estimated minimally important difference in the 
EQ-5D descriptive index that has been reported 
for other conditions is summarized in a recent re-
view as being between 0.037 and 0.069.24 No ef-
fect of treatment was seen with regard to the EQ 
visual-analogue scale scores. Therefore, it appears 
that levothyroxine had no clinically significant 
effects on generic health-related quality of life.
Muscle function has been described as being 
adversely affected by underactive thyroid.25 How-
ever, we found that hand-grip strength did not 
change from baseline significantly more with 
levothyroxine treatment than with placebo. Sim-
ilarly, it has been suggested that the speed of in-
formation processing is slowed in persons with 
subclinical hypothyroidism.4 However, we found 
no benefit with levothyroxine with regard to execu-
tive cognitive function as measured by the letter–
digit coding test. There also was no effect of 
treatment on blood pressure, weight, waist circum-
ference, body-mass index, or the Barthel Index 
or Instrumental Activities of Daily Living scores.
Participants were monitored closely for adverse 
effects from levothyroxine treatment. We found 
no increase in hyperthyroid symptoms after the 
initiation of treatment, and there was no sig-
nificant excess of serious adverse events of spe-
cial interest, including atrial fibrillation, heart 
failure, fracture, or new diagnosis of osteoporo-
sis. We believe that the slight excess of patients 
who had serious adverse events in the placebo 
group is a chance finding; the events were 
spread among a range of body systems, and no 
particular pattern was observed. Observational 
studies also have not shown any association of 
treatment of subclinical hypothyroidism with an 
increased risk of adverse events.26
Many older persons with biochemical results 
that are consistent with subclinical hypothyroid-
ism will have reversion to a euthyroid state if 
they are followed up without treatment. In total, 
approximately three out of five persons that we 
screened for entry into the trial on the basis of 
previously elevated thyrotropin levels had rever-
sion to normal thyroid biochemical results and 
were therefore excluded from the trial. These data 
are consistent with several other observational 
and trial cohorts that showed a high proportion 
of participants with an elevated thyrotropin level 
having reversion to biochemical euthyroidism 
during follow-up.4,27,28
Our trial has certain strengths. The trial in-
cluded a sufficient number of participants to pro-
vide good statistical power to show no benefits 
regarding symptoms. We used validated mea-
sures of thyroid-specific quality of life that have 
been shown to be sensitive to change,14,17 as well 
as a range of secondary outcomes of clinical rel-
evance. However, the trial also had certain limi-
tations. First, we chose to set a thyrotropin target 
of 0.40 to 4.60 mIU per liter with levothyroxine 
treatment, which is an approach that reflects 
recent guidelines, particularly for older persons.7 
However, some authorities have recommended a 
lower thyrotropin target (e.g., 0.40 to 2.50 mIU 
per liter).29 We cannot exclude the possibility that 
this more aggressive treatment approach might 
be beneficial. Second, since few participants had 
a baseline thyrotropin level of more than 10 mIU 
per liter, we cannot address whether there are 
benefits from treatment in this subgroup. Third, 
the symptom levels at trial entry were low, so we 
Figure 2. Thyrotropin Levels in the Placebo Group  
and Levothyroxine Group.
Shown are the results of a modified intention-to-treat 
analysis. Data are means, and error bars indicate 95% 
confidence intervals. Extended follow-up beyond 12 
months was conducted in a subgroup of patients, with 
a median duration of follow-up from baseline of 24.2 
months (interquartile range, 18.4 to 30.3) in the placebo 
group and 24.5 months (interquartile range, 18.4 to 30.5) 
in the levothyroxine group. P<0.001 for between-group 
differences in the thyrotropin level at 6 to 8 weeks, 12 
months, and extended follow-up. Analyses were adjust-
ed for stratification variables (country, sex, and starting 
dose of levothyroxine) and baseline thyrotropin level with 
the use of linear regression; data for the extended follow-
up visit were additionally adjusted for time to visit.
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cannot exclude the possibility of benefit in per-
sons with more marked symptoms. Fourth, we 
did not measure thyroid antibody levels. Anti-
body-positive patients are more likely than anti-
body-negative patients to have progressive hypo-
thyroidism and therefore may be more likely to 
have a benefit from long-term levothyroxine 
treatment.7 Finally, our trial was underpowered 
to detect any effect of levothyroxine on the inci-
dence of cardiovascular events or mortality. 
Therefore, we cannot exclude the possibility that 
treatment with levothyroxine may provide cardio-
vascular protection or cause harm.
In conclusion, this trial indicated that treat-
ment with levothyroxine in older persons with 
subclinical hypothyroidism provided no symp-
tomatic benefits.
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Variable
All Patients 
(N = 737)
Placebo Group 
(N = 369)
Levothyroxine Group 
(N = 368)
Hazard Ratio 
(95% CI)
Clinical outcome
Fatal or nonfatal cardiovascular event — no. (%) 38 (5.2) 20 (5.4) 18 (4.9) 0.89 (0.47–1.69)
Cardiovascular death — no. (%) 3 (0.4) 1 (0.3) 2 (0.5) —
Death from any cause — no. (%) 15 (2.0) 5 (1.4) 10 (2.7) 1.91 (0.65–5.60)
Serious adverse event
No. of patients with ≥1 serious adverse event 181 (24.6) 103 (27.9) 78 (21.2) 0.94 (0.88–1.00)†
No. of events 343 201 142 —
Adverse event of special interest
New-onset atrial fibrillation — no. (%) 24 (3.3) 13 (3.5) 11 (3.0) 0.80 (0.35–1.80)
Heart failure — no. (%) 9 (1.2) 6 (1.6) 3 (0.8) —
Fracture — no. (%) 17 (2.3) 8 (2.2) 9 (2.4) 1.06 (0.41–2.76)
New diagnosis of osteoporosis — no. (%) 7 (0.9) 4 (1.1) 3 (0.8) —
Withdrawal
Permanent discontinuation of trial regimen  
— no. (%)
160 (21.7) 79 (21.4) 81 (22.0) 1.06 (0.78–1.44)
Withdrawal from follow-up — no. (%) 41 (5.6) 22 (6.0) 19 (5.2) 0.84 (0.46–1.56)
*  This table includes serious adverse events and adverse events of special interest in the modified intention-to-treat population and data on 
withdrawals from trial regimen and follow-up. Hazard ratios were not calculated for cardiovascular death, heart failure, or new diagnosis of 
osteoporosis owing to the small number of events.
†  P = 0.05. Hazard ratios for treatment were obtained from a Cox proportional-hazards regression model predicting survival from randomized 
trial group and stratification variables (country, sex, and dose at randomization).
Table 3. Clinical Outcomes and Adverse Events.*
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